Watches blood for leftover lung cancer after surgery in adults
Follows adults with resected non-small cell lung cancer using blood tests for leftover cancer.
Plain-language title generated from the registry record
Registry title: Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
Key facts
- Where
- Foshan, Guangzhou, Shantou, and Zhongshan, ChinaSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IB-IIIA non-small cell lung cancer whose tumour was fully removed and whose blood tests show no molecular residual disease (MRD). They are followed closely without extra treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage IB-IIIA non-small cell lung cancer after complete surgical removal
- Earlier treatment
- No radiotherapy, chemotherapy or other anti-tumour treatment before joining
- Biomarker or test result
- Two rounds of MRD tests must confirm undetectable MRD at the landmark time point
Main reasons for not taking part
- Earlier radiotherapy, chemotherapy or other anti-tumour therapy
- Another cancer in the past 5 years
- Unstable systemic disease, such as active infection, high-risk hypertension, unstable angina or congestive heart failure
Read by machine on 12 November 2026.
Where in China
- The First People's Hospital of FoshanFoshan, ChinaContact: Weiquan GuTaking people
- Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical SciencesGuangzhou, ChinaContact: Wen-Zhao Zhong, MDTaking people
- Shantou Centeral HospitalShantou, ChinaContact: Yanlong YangTaking people
- the First Affiliated Hospital of Shantou University Medical CollegeShantou, ChinaContact: Zefeng XieTaking people
- Zhongshan City People's HospitalZhongshan, ChinaContact: Yi Liang, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guangdong Association of Clinical Trials
- Trial code
- NCT05457049
- Record updated
- 16 September 2026
- Original description
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.Read full original descriptionShow less
Dynamic Observational Strategy for Stage IB-IIIA Non-Small Cell Lung Cancer Patients After Complete Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.
Inclusion: Stage IB-IIIA non-small cell cancer patients who after complete resection; ≥18 years; Two-round MRD tests confirm landmark undetectable MRD; Expected survival ≥12 weeks; Expected survival ≥12 weeks; ECOG PS 1-2; Willing to accept MRD monitoring every 3 months for a total of 2 years after operation.
Exclusion: Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy; Patients with a history of other malignancies in the past 5 years; Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).